Blood Pressure Control and Exaggerated Blood Pressure Response in Nigerians with Essential Hypertension

Olugbenga O. Abiodun, Michael O. Balogun, Rasaaq A. Adebayo and Anthony O. Akintomide

Department of Medicine, Cardiology Unit, Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Osun State, Nigeria.

ABSTRACT
BACKGROUND: Blood pressure (BP) control in hypertensives is important in preventing cardiovascular (CV) morbidity and mortality. This work was done to assess control of BP among Nigerian hypertensives at rest and during exercise.

MATERIALS AND METHODS: A total of 85 male hypertensives were recruited consecutively and had clinical evaluation and treadmill (TM) exercise testing using the Bruce protocol. Independent t-test, chi-square, and Fisher’s exact tests were used to compare patients with controlled and uncontrolled BP using SPSS version 16 software. Adjustment for confounders was by logistic regression and general linear model.

RESULTS: Resting systolic BP (rSBP) (mmHg) and resting diastolic BP (rDBP) (mmHg) were significantly lower in the controlled group (115.0 ± 12.29, 133.1 ± 12.27, P = <0.001 and 76.00 ± 6.55, 91.4 ± 8.00, P = <0.001). The proportion of subjects with controlled BP was 37.7%. Adjusted peak SBP (PSBP) during exercise (mmHg) was significantly higher in the uncontrolled than in the controlled group (210.5 ± 27.31, 191.8 ± 20.77, P = 0.001). Adjusted exaggerated blood pressure response (EBPR) was found in 37 subjects (44%) in the uncontrolled group while seven subjects (0.1%) had EBPR in the controlled group (P = 0.003).

CONCLUSION: This study shows that EBPR is significantly higher in subjects with uncontrolled BP compared with those with controlled BP. Therefore, good BP control may be the key factor in preventing EBPR in hypertensives.

KEYWORDS: blood pressure control, exaggerated blood pressure response, hypertension, Nigerians

CITATION: Abiodun et al. Blood Pressure Control and Exaggerated Blood Pressure Response in Nigerians with Essential Hypertension. Clinical Medicine Insights: Cardiology 2014:8 53–56 doi: 10.4137/CMC.s15961.
RECEIVED: April 10, 2014. RESUBMITTED: May 19, 2014. ACCEPTED FOR PUBLICATION: May 21, 2014.
ACADEMIC EDITOR: Thomas E Vanhecke, Editor in Chief
TYPE: Original Research
FUNDING: Authors disclose no funding sources.
COMPETING INTERESTS: Authors disclose no potential conflicts of interest.
COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
CORRESPONDENCE: philabiodun@yahoo.com

This paper was subject to independent, expert peer review by a minimum of two blind peer reviewers. All editorial decisions were made by the independent academic editor. All authors have provided signed confirmation of their compliance with ethical and legal obligations including (but not limited to) use of any copyrighted material, compliance with ICMJE authorship and competing interests disclosure guidelines and, where applicable, compliance with legal and ethical guidelines on human and animal research participants.

Introduction
Hypertension is a global cause of cardiovascular (CV) morbidity and mortality. The burden of this disease is particularly heavy in the sub-Saharan part of Africa because of ignorance, poverty, inadequate healthcare, and erosion of traditional lifestyles. Apart from increasing prevalence of high blood pressure (BP) in this part of the world, BP control is also a challenge as BP control has been documented to be comparatively low at 5–10%. This challenge appears to be due to poverty, lack of proper education of patients, proliferation of untested alternative treatments, poly-pharmacy, and having to take medications for long periods of time for an apparently benign condition. The efficacy of BP treatment or control is traditionally assessed at rest and in certain cases; the advent of ambulatory BP monitoring has allowed BP control to be assessed on the go. It has been suggested that end-organ damage progresses despite control of resting BP. This may be related to the level of BP control and the BP response that is generated as individuals go about their routine daily activities. Kokkinos et al. in 2009 suggested that exercise BP reflects the BP during routine daily activities. Abnormal BP response like exaggerated blood pressure response (EBPR) during routine...
daily activities may therefore lead to target end-organ damage with consequent CV morbidity and mortality. The hypothesis for this work is that abnormal BP response like EBPR is dependent on the level of BP control. To assess this, this study looked at BP at rest and during exercise in essential hypertensives with or without adequate BP control.

**Subjects and Methods**

This study is a cross-sectional study. Eighty-five male subjects with essential hypertension were consecutively recruited at the outpatient clinic of the cardiology care unit of Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Osun State, Nigeria. They were evaluated clinically with history taking and physical examination, 12-lead resting ECG, transthoracic echocardiography, and treadmill (TM) exercise testing.

We included adult males and females above 18 years with the diagnosis of essential hypertension. Subjects with heart failure, severe hypertension (BP ≥ 180/110), secondary hypertension, diabetes mellitus (DM), contraindications to exercise testing, trained athletes, and conditions that may impair exercise testing were excluded from this study.

Subjects were exercised on the TM (Schiller CS-200, Switzerland) using the Bruce protocol. They exercised until exercise was completed or until an indication for exercise termination was met. BP was measured using a mercury sphygmomanometer (Accuson, Kris-Alloy, England) in the upright position and heart rate (HR) displayed on the digital HR meter was used for the study. The HR and BP were recorded at rest and during the last 30 seconds of each stage of exercise.

TM walking was demonstrated to subjects and was practiced prior to testing. The exercise laboratory and equipment conformed to the standard specifications for exercise testing and emergency care facilities and medications were on hand.

Controlled BP was defined as baseline BP < 140/90 mmHg and Uncontrolled BP as baseline BP > 140/90 mmHg according to the guidelines of the Eight Report of the Joint National Committee (JNC 8) on prevention, detection, evaluation, and treatment of high BP. EBPR was taken as SBP ≥ 210 mmHg. BP was measured by the same individual for all subjects using the same calibrated mercury sphygmomanometer (Accuson, Kris-Alloy, England). Subjects were seated comfortably with the arm supported at the level of the heart for five minutes before BP was taken. Appropriate cuff sizes were used.

Ethical clearance for the study was obtained from the Ethics and Research committee of the hospital, and subjects gave informed consent. Subjects’ confidentiality was ensured by the use of study identification serial numbers to replace their names.

**Data Analysis**

Data was analyzed using the SPSS version 16 software. Categorical variables were expressed as proportions and percentages, while continuous variables were expressed as means ± standard deviation or as ranges. Independent t-test was used to compare the means of the two BP control groups, while chi-square test was used for test of association. Where the expected value in any of the cells is <5, Fisher’s exact test was used. Logistic regression and multivariate general linear model were used to adjust for confounders. P < 0.05 was taken as statistically significant.

**Results**

Table 1 describes the characteristics of the two groups in the study population. Thirty-two of the subjects had controlled BP amounting to 37.7% of the total. The age (P = 0.064) and body mass index (BMI) (P = 0.515) in the subjects were similar in those with controlled BP and uncontrolled BP but duration of hypertension (DOH) was significantly higher in those with controlled BP (P < 0.001). The resting systolic BP (rSBP) and resting diastolic BP (rDBP) were significantly lower (P < 0.001) in subjects with controlled BP (115.0 ± 12.29 mmHg and 76.00 ± 6.55 mmHg) compared

| VARIABLE                | CONTROLLED        | UNCONTROLLED      | P-VALUE |
|-------------------------|-------------------|-------------------|---------|
| Age (years)             | 47.5 ± 7.8        | 43.7 ± 9.90       | 0.064   |
| DOH (months)            | 67.7 ± 5.2        | 52.7 ± 5.2        | < 0.001**|
| BMI (kg/m²)             | 27.0 ± 4.44       | 26.3 ± 4.86       | 0.515   |
| Family history of HBP슈 | 13 (40.6%)        | 26 (50.0%)        | 0.450   |
| rHR (b/m)               | 75.7 ± 11.92      | 81.2 ± 12.94      | 0.056   |
| rSBP (mmHg)             | 115.0 ± 12.29     | 133.1 ± 12.27     | < 0.001**|
| rDBP (mmHg)             | 76.00 ± 6.55      | 91.4 ± 8.00       | < 0.001**|

**Notes:** Controlled group < 140/90 mmHg, Uncontrolled group > 140/90 mmHg. Unless otherwise stated, results are expressed in mean ± standard deviation. n expressed in proportions (percentage). **Statistically significant P-value < 0.001, ṭ Chi square.

**Abbreviations:** DOH, Duration of hypertension from time of diagnosis; BMI, Body mass index; rHR, resting heart rate; rSBP, resting systolic blood pressure; rDBP, resting diastolic blood pressure.
with subjects with uncontrolled BP (133.1 ± 12.27 mmHg and 91.4 ± 8.00 mmHg).

The pattern of antihypertensive medication use is shown in Table 2. Commonly used antihypertensive medications were moduretic, angiotensin converting enzyme inhibitors (ACEI), and calcium channel blockers (CCB). No difference was found in antihypertensive medication use except in beta-blockers (BB), which was more in the uncontrolled group compared to controlled group \((P < 0.001)\).

In Table 3, CV responses by the two groups to maximum TM testing are shown. Both groups exercised for the same duration \((8.0 ± 1.30 \text{ minutes})\ in the controlled and 8.4 ± 1.51 \text{ minutes} in the uncontrolled, \(P = 0.208\)). The PSBP and rate pressure product (RPP) were significantly lower \((P = 0.001\) and \(P = 0.009)\ in the controlled BP group \((191.8 ± 20.77 \text{ mmHg}) and 288.2 ± 54.00 \text{ mmHg bpm} × 10^{-2}\) compared with the uncontrolled BP group \((210.5 ± 27.31 \text{ mmHg}) and 326.1 ± 68.72 \text{ mmHg bpm} × 10^{-2}\). Both remained significantly lower in the controlled group after adjusting for DOH \((P = 0.001\) and \(P = 0.03)\. There was a significant crude \((P < 0.001)\ and adjusted \(\text{(for DOH)}\ \text{difference} \(P = 0.003)\ in the EBPR, with higher EBPR in the uncontrolled BP group \((44\%)\ than in the controlled group \((0.1\%)\.

**Discussion**

The percentage of BP control in this study is low at 37.7%. This is similar to low percentage or prevalence that have been previously reported in the literature.\(^1\) Also, rSBP and DBP were significantly lower in the controlled BP group despite similar age, BMI, and antihypertensive medications (with the exception of BB) in the two groups. Documented predictors of BP control in the literature include poverty,\(^16\) low education,\(^27\) lower age, BMI, DM, antihypertensive medications used, and adherence to and persistence with antihypertensive treatment plan.\(^18\) In this work, age, BMI, and the commonly used antihypertensive medications showed no effect on BP control. It is probable that adherence to antihypertensive treatment plan is one of the factors influencing BP control in this group of subjects, but this was not evaluated in this study. There is a need for more concerted and integrated public health and physician driven measures to combat major and peculiar reasons for this low prevalence, namely poverty\(^16\) and low education.\(^17\) This is because people who are poor and ignorant are less likely to be aware that they are hypertensive and may be unable to procure medications to treat the disease, thereby affecting compliance.

Commonly used antihypertensive medications in this study were diuretics, CCBs, and ACEIs. This is in keeping with the recommendations of the JNC 8 committee on prevention, detection, evaluation, and treatment of high BP for blacks.\(^23\) Adherence to these recommendations by physicians in the sub-Saharan Africa is encouraging as it shows that efforts can now be concentrated on other causes of failure of BP control, particularly adherence to antihypertensive plan by patients. This appears to be a major challenge as a result of poverty, poor awareness, and education about hypertension in many low-income areas of sub-Saharan Africa.

Office or resting BP has been documented as an independent predictor of EBPR.\(^23\) In this study, EBPR adjusted for DOH was significantly lower in those with controlled BP or normal resting BP. Also, PSBP adjusted for DOH was found to be significantly lower in those with controlled BP. This suggests that the level of BP control may be an important independent factor contributing to EBPR as documented in the literature.\(^23\) Other factors that predict EBPR include QT dispersion, DM, and increased age.\(^24\) In this study, age was not different for the two BP control groups while subjects with

---

**Table 2. Pattern of antihypertensive use.**

| MEDICATION    | CONTROLLED | UNCONTROLLED | P-VALUE |
|---------------|------------|--------------|---------|
| Moduretic     | 21 (65.6%) | 26 (49.1%)   | 0.137   |
| CCB           | 9 (28.1%)  | 15 (28.3%)   | 0.986   |
| ACEI          | 17 (53.1%) | 31 (58.5%)   | 0.629   |
| β-blockers    | 3 (9.4%)   | 11 (20.8%)   | <0.001**|
| ARB           | 1 (3.1%)   | 1 (1.9%)     | 1.00    |
| Methylldopa   | 1 (3.1%)   | 1 (1.9%)     | 1.00    |
| ACEi+H        | 0 (0%)     | 4 (7.5%)     | 0.292   |
| ARB+H         | 1 (3.15)   | 3 (5.7%)     | 1.00    |

**Notes:** Moduretic (25 mg hydrochlorothiazide + 5 mg amiloride). **Statistically significant \(P\)-value \(< 0.001\), \(\text{Fisher’s exact test. Abbreviations: CCB}, \text{Calcium channel blockers (amlodipine, nifedipine, and felodipine); ACEI}, \text{Angiotensin converting enzyme inhibitors (lisinopril, ramipril, and enalapril); β-blockers (atenolol), ARB, Angiotensin receptor blockers (valsartan, telmisartan, losartan); Methylldopa, ACEi+H, ACEI (ramipril)+hydrochlorothiazide, ARB+H, Angiotensin receptor blocker (telmisartan)+hydrochlorothiazide.**

**Table 3. Cardiovascular responses during exercise in controlled and uncontrolled BP groups.**

| VARIABLE      | CONTROLLED   | UNCONTROLLED | P-VALUE  |
|---------------|--------------|--------------|----------|
| DOE (min)     | 8.0 ± 1.30   | 8.4 ± 1.51   | 0.208    |
| MHR (bpm)     | 150.2 ± 2.54 | 154.2 ± 20.59| 0.415    |
| %THR          | 87.0 ± 12.38 | 87.5 ± 11.05 | 0.827    |
| PSBP (mmHg)   | 191.8 ± 20.77| 210.5 ± 27.31| 0.001*, 0.001**|
| PDBP (mmHg)   | 73.6 ± 14.74 | 74.6 ± 13.75 | 0.752    |
| RPP (mmHg, bpm × 10^{-2}) | 288.2 ± 54.00 | 326.1 ± 68.72 | 0.009*, 0.03* |
| EBPR          | 7 (0.1%)     | 37 (44%)     | <0.001**, 0.003**|

**Notes:** Unless otherwise stated, values are expressed as mean ± standard deviation, \(\chi^2\) Chi square. **Statistically significant \(P\)-value \(< 0.001\), \(\text{Adjusted \(P\)-value (multivariate general linear model).}** Logistic regression. **Abbreviations:** DOE, Duration of exercise; MHR, Maximal heart rate; % THR, Maximum heart rate expressed as percentage of age predicted; PSBP, Peak systolic blood pressure; PDBP, Peak diastolic blood pressure; RPP, Rate pressure product.
DM were excluded and QT dispersion was not assessed. It is likely, therefore, that adequate control of BP may completely eliminate the propensity toward EBPR in patients with essential hypertension.

The prevalence of EBPR adjusted for DOH in the uncontrolled group is 44%. This is similar to 45% prevalence in an earlier work in the same exercise laboratory.25 Also, EBPR in the uncontrolled group is significantly higher than in the controlled group (0.1%). This suggests that the major determinant of EBPR in essential hypertension appears to be BP control. This high percentage in the uncontrolled group, therefore, calls for better BP control to stem CV morbidity and mortality. This can be achieved by prescription of antihypertensive medications according to guidelines, public health education about hypertension, and poverty alleviation. With the presence of EBPR in some of the patients with controlled BP, we suggest further work to look into factors predicting EBPR in those with apparently normal resting BP.

**Conclusion**

This study shows that good BP control may be important in preventing EBPR, which has been found to increase CV morbidity and mortality. A large scale study is needed to validate the findings of this study and to identify other predictors of EBPR in hypertensives with controlled and uncontrolled resting BP.

**Limitation of Study**

This is a predominantly male study because only few females volunteered for the study. Also, the sample size for this work is relatively small.

**Author Contributions**

Conceived and designed the experiments: OOA and MOB. Analyzed the data: OOA. Wrote the first draft of the manuscript: OOA. Contributed to the writing of the manuscript: OOA, MOB, RAA and AOA. Agree with manuscript results and conclusions: OOA, MOB, RAA and AOA. Jointly developed the structure and arguments for the paper: OOA, MOB, RAA and AOA. Made critical revisions and approved final version: OOA, MOB, RAA and AOA.

**REFERENCES**

1. Seedat YK. Hypertension in developing nations in sub-Saharan Africa. J Hum Hypertens. 2000;14(10–11):739–47.
2. Suleiman IA, Amogu EO, Ganiyu KA. Prevalence and control of hypertension in a Niger Delta semi urban community, Nigeria. Pharm Pract (Granada). 2013;11(1):24–9.
3. Seedat YK. Impact of poverty on hypertension and cardiovascular disease in sub-Saharan Africa. Cardiovasc J Afr. 2007;18(5):316–20.
4. Pearson TA. Education and income: double-edged swords in the epidemiology of cardiovascular disease. Ethn Dis. 2003;13(2 suppl 2):S158–63.
5. Banegas JR, Ruiuope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension and with treated hypertension. Eur Heart J. 2014 doi: 10.1093/eurheartj/ehu016.
6. Lund-Johansen P. Central haemodynamics in essential hypertension at rest and during exercise: a 20-year follow-up study. J Hypertens. 1989;7:52–5.
7. Rowland SG, Brown B, Kirk KA, et al. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:684–8.
8. Alcazar JM, Rodicio JL, Ruiuope LM. Long-term diuretic therapy and renal function in essential hypertension. Am J Cardiol. 1990;65:51–4.
9. Kokkinos P, Manolou A, Pittaras A, et al. Exercise capacity and mortality in hypertensive men with or without additional risk factors. Hypertension. 2009;53:494–499.
10. WHO. WHO/ISH hypertension guidelines. J Hypertens. 1999;17:151–83.
11. Chairmain BR. Exercise stress testing. In: Bonov RO, Mann DL, Zipes DP, Libby P, eds. Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia: Elsevier Saunders; 2012,168–92.
12. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694–740.
13. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
14. Kasiskogias A, Tsiofus C, Thomopoulos C, et al. A hypertensive response to exercise is prominent in patients with obstructive sleep apnea and hypertension: a controlled study. J Clin Hypertens (Greenwich). 2013;15(7):497–502.
15. Ha DA, Goldberg RJ, Allison JJ, Chu TH, Nguyen HL. Prevalence, awareness, treatment, and control of high blood pressure: a population-based survey in Thai Nguyen, Vietnam. PLoS One. 2013(8):e66792.
16. Chow CK, Teo KK, Kangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.
17. Lloyd-Sherlock P, Beard J, Minuci N, Ebrahim S, Chatterji S. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43(5):136–28.
18. Bramley TJ, Gerhino PP, Nightengale BS, Frich-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239–45.
19. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig. 2008;28(11):713–14.
20. da Silva PM. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on ambloplatin/valsartan. Clin Drug Investig. 2010;30(9):625–41.
21. Shelley D, Tseng TY, Andrews H, et al. Predictors of blood pressure control among hypertensives in community health centers. Am J Hypertens. 2011;24(12):1318–23.
22. Romanelli RJ, Schiro TA, Jukes T, Wong KS, Ishisaka DY. Disparities in blood pressure control within a community-based provider network: an exploratory analysis. Ann Pharmacother. 2011;45(12):1473–82.
23. Karavelioglu Y, Karapinar H, Gul İ, et al. Blood pressure response to exercise is exaggerated in normotensive diabetic patients. Blood Press. 2013;22(1):21–6.
24. Ertaş F, Yavuz C, Kaya H, et al. The relationship between QT dispersion and exaggerated blood pressure response to exercise stress testing. Clin Exp Hypertens. 2013;35(6):470–4.
25. Balogan MO, Ladipo GOA. Cardiovascular responses to exercise in essential hypertension. West Afr J Med. 1990;9:272–8.